GSK Industry symposium

BCMA-Targeted Therapies – A New Combination Partner in Early Relapsed/Refractory Multiple Myeloma

Thursday, May 11, 2023
13:00–14:00 CEST

Speakers

Katja Weisel, MD (Chair)
Deputy Director and Associate Professor
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Evangelos Terpos, MD, PhD
Associate Professor of Hematology
National and Kapodistrian University of Athens School of Medicine
Athens, Greece

Suzanne Trudel, MD, MSc
Consultant, Princess Margaret Cancer Centre
Associate Professor, University of Toronto
Toronto, Canada

Agenda

5 min Welcome and short introduction
Katja Weisel, MD
10 min Exploring the rapidly evolving treatment landscape in RRMM
Katja Weisel, MD
10 min Evaluating the clinical evidence for anti-BCMA therapy combination strategies in early RRMM
Panel discussion moderated by Evangelos Terpos, MD, PhD
10 min Optimizing benefit-risk with anti-BCMA agents in earlier lines of MM therapy
Panel discussion moderated by Suzanne Trudel, MD, MSc
10 min Roundtable discussion: global expert perspectives on the real-world management of patients with RRMM
Katja Weisel, MD; Suzanne Trudel, MD, MSc; Evangelos Terpos, MD, PhD
10 min Audience Q&A
Katja Weisel, MD; Suzanne Trudel, MD, MSc; Evangelos Terpos, MD, PhD
5 min Closing remarks
Katja Weisel, MD

Session Objectives

  • Understand the rapidly evolving treatment landscape for RRMM
  • Review updated evidence on the impact of anti-BCMA monotherapies in RRMM
  • Explore emerging data on the use of BCMA-targeting agents in combination with established therapies in early RRMM
  • Discuss the approaches for improving benefit-risk with BCMA-targeting agents in earlier lines of MM therapy
  • Explore the practical considerations on the management of patients with RRMM